In a previous communication, Ellis and I 1 reported that the serum of patients who were treated intravenously with salvarsan or neosalvarsan had a definite spirocheticidal action. This action was increased by heating the serum at 56 0 C. for one-half hour. By an indirect method it was shown, first, that the heat destroyed some inhibitory substance in the serum, and, second, that it directly increased the action of the serum-salvarsan mixture. The beneficial effects of intraspinal injections of serum in the treatment of syphilis of the central nervous system have been attributed in part to this spirocheticidal substance. Because of the variable quantities of salvarsan in the serum of patients after intravenous injections of the drug, Ogilvie 2 has suggested a method for the preparation of salvarsanized serum in which a small quantity of faintly alkaline solution of salvarsan is added to serum, the mixture incubated and heated at 56 0 C. for onehalf hour. The object of the present work was to study the spirocheticidal effect of serum salvarsanized in vitro.
Following our first communication, StUhmer 3 showed that the serum of salvarsan-treated rabbits had a trypanosomicidal action which was markedly increased by heating. He also showed that heating increased the intensity of the paradimethylamidobenzaldehyde color reaction for salvarsan, and that the intensity of the color reaction and the trypanosomicidal power were more or less parallel. However, by studying the serum daily for 10 days following the intravenous injection of salvarsan, he demonstrated that the trypanosomicidal action of heated serum persisted several days after the color reaction had disappeared. He 4 next showed that the trypanosomicidal action of the serum of salvarsan-treated rabbits persisted longer than that of neosalvarsan-treated rabbits, and that the serum of rabbits treated intramuscularly with salvarsan had very little action. Ehrlich 'Swift, H. F., and Ellis, A. W. M., J. Exp. Med., 1913, xviii, 435. 2 Ogilvie, H. S., J. Am. Med. Assn., 1914 , xiii, 1936 . 3 Stiihmer, A., Manch. med. Woch., 1914 , lxi, 745. 4 Stiihmer, Munch. med. Woch., 1914 , Ixi, 1101 suggested that the effect of heat was to break up a loose combination which had taken place between the salvarsan and some substance in the serum, thus setting free the salvarsan which acts on the trypanosomes or spirochetes; but Sttiihmers attributed the increased action of heated serum to an increased oxidation. He finally studied the effect of oxidation and reduction on the salvarsanized rabbit serum and showed that oxidation did not increase the trypanosomicidal power of either unheated or heated serum, and also that reduction with weak sodium hydrosulphite solution did not decrease the power of the unheated serum. Reduction, however, did affect the heated serum by removing the increased trypanosomicidal action which had been produced by heating. In other words, the reduction caused the heated serum to act in the same manner as unheated serum. As Stihmer's experiments were not performed with diminishing dilutions of serum, but with serum obtained on successive days after the administration of salvarsan, the exact relation of heating, oxidation, and reduction are not entirely clear.
Methods.
In the present study a strain of Spirochceta duttoni, propagated in white mice, has been employed. The suspension for performing the test was prepared by bleeding a well infected mouse into warm normal saline solution, and diluting with normal saline solution until the required number of spirochetes per field was obtained. Equal quantities of this suspension and the dilution of serum to be tested were mixed thoroughly and incubated at 37°C. for 1 hour. 1 cc. of the mixture, representing 0.5 cc. of the spirochete suspension, was injected into mice intraperitoneally. The blood of the infected mice was examined daily with the dark-field microscope. The intensity of the subsequent infection is indicated by the average count of twenty fields, as shown in the protocols. The salvarsanized serum was prepared as follows: A slightly alkaline watery solution of salvarsan was diluted to 1: 2,000 with 0.5 per cent saline solution. One part of this was added to nine parts of serum, making a dilution of 1:20,000, and from this the subsequent dilutions were made with normal serum, or normal salt solution, as the experimental conditions required.
EXPERIMENTAL.
The serum-salvarsan mixture prepared in vitro had a definite spirocheticidal action. This point was previously demonstrated by Dilutions of salvarsan in normal serum were made, incubated, and each dilution divided into two portions; one of each portion was heated at 56 0 C. for one-half hour. A syphilitic patient weighing 71 kilos received 0.3 gm. of salvarsan intravenously (Sera C and D), and another weighing 68 kilos received 0.5 gm. (Sera E and F). Blood was taken from each after 1 hour, allowed to coagulate, centrifugalized, and the serum removed immediately. The serum from each was divided into two portions, one of which was heated at 56°C. for one-half hour, and then diluted as indicated. The spirochetal suspension, containing between six and eight spirochetes per field was mixed with the various sera; it was then incubated for 1 hour and injected into mice.
1
... Gonder. 6 Heating the mixture at 56 0 C. for one-half hour increased this action. The effect of heating was studied in a series of seven experiments; four times the heating doubled the strength of the serum, twice it quadrupled it, and once increased it eightfold. In terms of absolute amounts of salvarsan in the heated serum, in three instances the spirocheticidal action was complete in a concentration of 0.025 mg., in three others of 0.012 mg., and once of 0.006 mg. per cc. of serum. This variation was probably due to the difference in the number of spirochetes in the suspension in the several experiments. In Experiment 1 (Table I ) the heated serum salvarsanized in vitro was more effective in a dilution of 1: 80,000 than the patient's serum, and the heating had less relative influence on the patient's serum. It should be noted here that the serum was removed from the clot within an hour of the time the patient was bled. In this respect this part of the experiment differs from those previously reported. In our earlier work the serum always stood over night before separation from the coagulum.
Although the spirocheticidal action of the unheated serum which was separated immediately was only slightly less than that which stood on the clot over night, a greater difference was noted between the two sera after they were heated. Heating increased the action of the serum which had been in contact with the clot over night much more than it did the serum removed from the clot immediately (Table II) . Six different experiments were performed with the serum of patients obtained after salvarsan treatment. In four in which the serum was separated immediately, the increase in spirocheticidal action of heated serum was considerably less marked than in two in which the serum was removed from the clot 24 hours after the bleeding (Table  VII, G and H) .
After the demonstration of this point with the serum of salvarsantreated patients, it seemed desirable to determine whether the serum from blood salvarsanized in vitro would act in the same manner. The results of this experiment are shown in Table III . Here the two unheated sera were again spirocheticidal in the same dilution, although Serum A in 1:2 dilution inhibited the infection 2 days 'Gonder, R., Z. Immunititsforsch., Orig., 1914, xxi, 309. 
Control. S1 Injected immediately. + 0+ +0 + A patient weighing 65 kilos received 0.4 gm. of salvarsan intravenously. 50 cc. of blood were withdrawn after one-half hour, allowed to coagulate, centrifugalized, and 10 cc. of serum pipetted off. The remainder of the serum was allowed to stand on the clot over night, after which it was centrifugalized and pipetted off. Each serum was divided into two lots, and one of each heated at 56°C. for one-half hour. Dilutions of each series were made with normal saline; the spirochetal suspension containing from four to five spirochetes per field was added; it was then incubated for 1 hour and injected into mice.
longer than did Serum C in the same solution. When the two sera were heated, however, the one that was immediately removed from the clot was more potent than the one that stood on the clot over night. This is the opposite of what occurred with patient's serum. The explanation of this difference is not clear, but it is suggested that the salvarsan undergoes some change while circulating in the body which it does not undergo when it is mixed with blood in the testtube. This may be due to the fact that in the body it is in contact with blood in the fluid condition for a longer period, hence oxidative conditions are more complete; or that contact with the tissues brings 2 cc. of a 1:2,000 dilution of salvarsan were mixed with 18 cc. of freshly drawn human blood. This was divided into two equal portions and allowed to coagulate. The first was then centrifugalized and the serum removed from the clot; the second was allowed to stand over night in the ice box, after which it was centrifugalized and the serum removed. Both lots of serum were divided into two portions, and one of each was heated at 56C. for one-half hour. Dilutions of each of the four series were made with normal saline solution. The suspension of spirochetes, containing three to four spirochetes per field, was added; it was then incubated for 1 hour and injected into mice. about some change in it which is not effected in the test-tube. From this point of view, at least, the use of serum of salvarsan-treated patients seems justified. 1 cc. of a 1: 2,000 dilution of salvarsan was mixed with 9 cc. of normal human serum (making a dilution of 1:20,000), incubated for 1 hour, divided into two portions, A, unheated, and B, heated, at 56 0 C. for one-half hour. 1 cc. of the same salvarsan dilution was mixed with 9 cc. of freshly drawn blood, incubated for 1 hour, centrifugalized, and the serum pipetted off and divided into two portions, C, unheated, and D, heated the same as B. The various series were then diluted with normal saline solution; the spirochetal suspension, containing eight to ten spirochetes per field, was added; it was then incubated for 1 hour and injected into mice.
Experiment 4 (Table IV) was devised to determine whether a more potent serum resulted from the addition of salvarsan to serum or to blood. Both were prepared on the same day and tested within 2 hours of the time of preparation. In both the unheated and heated condition the serum prepared by the direct addition of salvarsan was more spirocheticidal than the serum from blood to which salvarsan had been added.
The demonstration that heating increased the spirocheticidal action of the salvarsan-serum mixture permitted a study of the effect of heat on each component of the mixture. This experiment confirmed by a direct method what was previously demonstrated by an indirect method, that part of the action of the heat was to remove some inhibitory substance from unheated serum. In Series C, Table V, the heating of the serum before the salvarsan was added resulted in producing a more active mixture than in Series A where the mixture was not subjected to heat. But the action of the mixture in Series C was not so strong as in Series B where the two were heated together. Series D demonstrated that part of the effect of the heat was directly upon the salvarsan, for although the heated salvarsan was combined with unheated serum, which contained inhibitory substances, the mixture was more spirocheticidal than the unheated mixture, but again not so active as the heated mixture. That the total result of the heat is due to a summation of these two effects is shown in Series E where the two components were combined after heating. This mixture was stronger than either C or D and had practically the same effect as in Series B where the two were heated together; the only exception noted was in Mouse E4 where there was a very slight infection on the 3rd day.
The relative effect of heat upon removal of inhibitory substance in the serum and upon increasing the spirocheticidal action of salvarsan was only slightly brought out in this experiment, where the infection of Mouse C4 was less than that of D4; but in two other similar experiments, in which the controls showed a more intense infection, the 1:80,000 mouse in the C series was completely protected, while the same mouse in the D series showed distinct infection. The effect of the heat seems, therefore, to be relatively greater in the removal of inhibitory substance from the serum than in directly increasing the activity of the salvarsan. The serum was from a patient with cured (?) syphilis. Wassermann reaction negative. Series A and B were prepared as in Table I . In Series C the serum was heated at 56 0 C. for one-half hour and then the salvarsan was added and dilutions were prepared. In Series D the salvarsan (1: 2,000 dilution) was heated at 56 0 C. and then diluted with unheated serum. At the end of the period of heating the salvarsan was only very slightly turbid. Portions of the heated serum of Series C and heated salvarsan of Series D after heating were mixed in the usual way. The spirochetal suspension, containing between four and six spirochetes per field, was mixed with the various sera; it was then incubated for 1 hour and injected into mice. Dilutions of salvarsan were made in normal serum in the usual way. Similar dilutions of neosalvarsan in serum were prepared, 0.15 gm. of neosalvarsan being considered the equivalent of 0.1 gm. of salvarsan. Each dilution was divided into two portions, one of which was heated at 56°C. for one-half hour. The spirocheticidal suspension, containing six to eight spirochetes per field, was mixed with the sera; it was then incubated and injected into mice.
In comparing the serum withdrawn from salvarsan-and neosalvarsan-treated rabbits on successive days after treatment, Stiihmer showed that the duration of the trypanosomicidal action of both was practically the same if the serum was unheated, and that there was but little difference between heated and unheated serum of the neosalvarsan-treated rabbits. The heated serum of salvarsan-treated rabbits, however, was trypanosomicidal several days longer than the same serum not heated. He concluded, therefore, that heating had less effect on neosalvarsanized serum. His method of experimentation did not lend itself to a comparative study of the effect of heating, because he used only one dilution of each serum. His results give rather the duration of trypanosomicidal effect after treatment, and the comparative rate of elimination of salvarsan and neosalvarsan. Experiment 6 (Table VI) showed that neosalvarsan is more active against Spirochtcta duttoni than salvarsan, but that heating increases the action of both. In each instance the spirocheticidal action of the heated serum was double that of the unheated. Castelli 7 similarly showed that neosalvarsan was more active against Spirochatta recurrentis than salvarsan, the ratio being 1:600 to 1:400. The curative dose of both drugs was the same for Spirochceta gallinarum, while double the dose of neosalvarsan, compared with salvarsan, was required to cure syphilis in rabbits. Thus the comparative curative dose of the two drugs varies according to the microorganism tested. This experiment proves only that heat had the same relative effect on both salvarsan-and neosalvarsan-serum mixtures. The proof that a mixture of salvarsan in normal serum had a definite spirocheticidal action suggested that this action might be enhanced if the salvarsan were mixed with the serum of a salvarsantreated patient. The results of an experiment to determine this point are shown in Table VII . The lethal dose of the salvarsan in normal serum for the spirochete was 0.012 mg. The patient's serum (heated at 56°C.) was completely spirocheticidal in a dilution of 1: 1. When half of this dilution was mixed with 0.006 mg. of salvarsan the mixture was completely spirocheticidal, and even when the same amount of salvarsan was mixed with a 1:4 dilution of serum only a slight infection of the mice occurred. Incidentally, the effect of heating salvarsan-treated patient's serum after it has stood 24 hours is well Dilutions of salvarsan in normal serum were made in the usual way and heated (Series B). A patient with tabes, weighing 70 kilos, received 0.35 gm. of salvarsan intravenously. Blood was withdrawn one-half hour later and allowed to stand over night. It was then centrifugalized and the serum pipetted off, and three series of tubes, E, G, and H, were set up, and the serum was diluted with normal saline solution in Tubes 2 and 3. To each of the tubes of Series E, 0.006 mg. in 0.25 cc. of normal serum was added, after which Series E and G were heated at 56°C. for one-half hour. The spirochetal suspension, containing six to eight spirochetes per field, was added to each tube; it was then incubated for 1 hour and injected into mice. brought out in the control series, G and H. This experiment seems to prove conclusively that the most potent spirocheticidal mixture with a given amount of salvarsan is to be expected from a combination of salvarsan with the serum of a salvarsan-treated patient, the blood having been allowed to stand over night before the serum is separated. DISCUSSION. Following the introduction of intraspinal injection of serum in the treatment of patients with syphilis of the central nervous system, numerous workers attempted to inject intraspinally salvarsan or neosalvarsan in weak dilutions. When more than 1 mg. has been repeatedly injected several observers have noted symptoms of myelitis in the lower segment of the cord. Marinesco and Minea 8 have observed that neosalvarsan diluted with serum is less irritating than when diluted with normal salt solution. Fordyce, and Ogilvie, 2 who have had the greatest experience with the Ogilvie method of preparation of salvarsan serum, now advise that only a fraction of a milligram of salvarsan be mixed with the serum for intraspinal injection. Clinical evidence seems, therefore, to indicate that only small amounts of salvarsan or neosalvarsan can be safely injected into the subdural space. The main objection to subdural therapy of cerebrospinal syphilis has been that the serum injected contained such small amounts of salvarsan. Obviously it is necessary to keep the amount of any therapeutic agent below the injurious dose. Therefore, with the evidence at hand only small amounts of the drugs at our disposal can be used. Our object then must be to use them in the least injurious and most potent form. From the evidence brought forward in the experiments in this communication, this would be the addition of small amounts of salvarsan or neosalvarsan to the serum of salvarsan-treated patients. This serum preferably should be allowed to remain in contact with the clot over night, and should be heated after the addition of the salvarsan. Although this technique is complicated, it could be easily carried out in clinics where large numbers of patients are treated, or if the salvarsan is procurable in ampules containing small amounts, so that dilutions for addition of the drug to the serum might be economically prepared.
1. Addition of salvarsan to serum in vitro produces a spirocheticidal mixture which is increased in potency by heating.
2. The heated serum of salvarsan-treated patients is more spirocheticidal if it has been in contact with the clot over night than if it has been separated immediately after coagulation. This is not true with the serum from blood which has been salvarsanized in vitro.
3. The addition of salvarsan directly to serum produces a more potent mixture than results from the serum from blood to which salvarsan has been added in equivalent amounts.
4. The increase in activity of salvarsanized serum produced by heating to 560C. is due in part to the removal of inhibitory substances in the serum and in part to a direct increase in spirocheticidal power in the heated salvarsan.
5. Both salvarsanized and neosalvarsanized serum are rendered more spirocheticidal by heating.
6. A more active spirocheticidal mixture is produced by mixing small amounts of salvarsan with the serum of a salvarsan-treated patient than by mixing the same amount with normal serum.
